Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jaguar Health Inc
(NQ:
JAGX
)
1.175
-0.045 (-3.69%)
Streaming Delayed Price
Updated: 10:34 AM EDT, Oct 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Jaguar Health Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics
January 24, 2022
Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS) For SBS, Napo Therapeutics has...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones
January 13, 2022
2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
January 12, 2022
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDA U.S. veterinarians,...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
January 04, 2022
The Canalevia.com website, a resource for veterinarians and dog owners, is now live Canalevia™-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs
December 22, 2021
By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
December 21, 2021
By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs
December 20, 2021
SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics...
From
Jaguar Health, Inc.
Via
AccessWire
European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Health’s Italian Subsidiary, for Short Bowel Syndrome
December 13, 2021
The recognition of Orphan Drug Designation in Europe for crofelemer for this rare disease is the first key milestone of Napo EU under the company's exclusive license agreement with Jaguar Health SAN...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
December 10, 2021
Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company’s Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)
December 06, 2021
Content from the discussion will be featured in upcoming "Diarrhea Dialogues: Part 2" SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it is hosting...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
November 19, 2021
Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Reports 2021 Third Quarter Financial Results
November 17, 2021
Mytesi® prescription volume increased 7.6% in Q3 2021 over Q2 2021 Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million Company expects to...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health's Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager
November 16, 2021
REMINDER: Jaguar to host investor webcast Wednesday, November 17th at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcast SAN FRANCISCO, CA...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time
November 15, 2021
Click here to register for webcast Company plans to file Q3 2021 10-Q on November 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates
November 10, 2021
Click here to register for webcast Company plans to file Q3 2021 10-Q on November 15, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer
November 08, 2021
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the appointment by Napo EU S.p.A., the company's Italian subsidiary, of Annabella Amatulli as chief...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch
November 02, 2021
Canalevia™-CA1 is the first and only oral plant-based prescription drug candidate for CID in dogs Jaguar kicks off educational awareness contest in honor of International Jaguar Day; Click here to...
From
Jaguar Health, Inc.
Via
AccessWire
The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed
November 01, 2021
The combined entity is named Napo EU S.p.A. SAN FRANCISCO, CA / ACCESSWIRE / November 1, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the merger of its Italian subsidiary Napo EU...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 29, 2021
SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that, effective October 25, 2021, the Company granted nonstatutory...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing
October 25, 2021
Merger expected to be effective within a week The combined entity will be named Napo EU S.p.A. Merger effects the exclusive license agreement between Jaguar and Napo EU S.p.A. including up-front...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.
October 07, 2021
Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger Results accepted for third-party, investigator-initiated Phase 2...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award
September 30, 2021
Award celebrates Ms. Conte's 30-year, unrelenting commitment to supporting Indigenous communities in the Amazon and responsibly harvesting and commercializing the first-ever plant-based oral medicine...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Death
Exposures
Death
Product Safety
Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021
September 27, 2021
Leading oncologists discuss importance of supportive care for cancer patients to address debilitating diarrhea resulting from cancer therapy Virtual event 1:00 PM to 2:10 PM Eastern Registration open...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs
September 23, 2021
Jaguar planning for launch of Canalevia™ for CID in dogs this December Canalevia is the first and only oral plant-based prescription drug candidate for CID in dogs SAN FRANCISCO, CA / ACCESSWIRE /...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time
September 16, 2021
Click here to register for webcast Jaguar kicks off educational awareness contest in honor of Indigenous Peoples' Day; Click here to enter SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2021 / Jaguar...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency
September 15, 2021
The conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo Pharmaceuticals...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
September 14, 2021
Participating investors include Jaguar CEO and CFO, Dragon SPAC S.p.A. sponsor Josh Mailman, and plant-based pharmaceutical manufacturing pioneer Indena S.p.A. Company to host investor webcast Monday,...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director
September 09, 2021
Appointments represent Jaguar's focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split
September 03, 2021
- Reverse split approved by majority of common stock shareholders at December 2020 special meeting of stockholders - Shares of Jaguar common stock to begin trading on split-adjusted basis on September...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders
September 03, 2021
Proposals 1, 2, 4, 5 & 6 approved SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.